MGL-3196 (resmetirom) is an investigational drug primarily developed for the treatment of hypercholesterolemia and non-alcoholic steatohepatitis (NASH), conditions characterized by high levels of cholesterol and fat accumulation in the liver. It works by selectively activating thyroid hormone receptor beta (THR-β) in the liver, which helps to increase the metabolism of cholesterol and lipids, reduce their levels in the bloodstream, and promote hepatic fat reduction. This mechanism makes it particularly promising for patients with familial hypercholesterolemia, a genetic disorder leading to severely elevated cholesterol levels and increased cardiovascular risk, as well as for metabolic disorders associated with insulin resistance. Clinical studies have shown potential in improving lipid profiles by lowering LDL cholesterol and triglycerides while increasing HDL cholesterol, and it may also support weight management and cardiovascular health. Current research focuses on confirming long-term safety and efficacy for potential therapeutic use.